A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

But more detail is awaited, especially on toxicity.

The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.

The ESMO regular abstract lift reveals first human datasets for several projects.

Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.

And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.

The group toplines a phase 2 win with Alphamedix.

The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.

And Treeline and HengRui also get in on the pan-RAS act.